tbuckley/cabot-search huggingface dataset:
POS0689 GENICULAR NERVE BLOCK IN JUVENILE IDIOPATHIC ARTHRITIS: A RANDOMIZED CLINICAL TRIAL
Authors: A. Radwan, H. Eitta, A. Elsaman
Journal: Annals of the Rheumatic Diseases (2022)

Background Genicular nerve block (GNB) showed promising results in improving pain, function, and inflammation in adults with rheumatoid arthritis suffering from persistent knee arthritis (1). Objectives This study aimed at testing the effect of GNB in juvenile idiopathic arthritis (JIA) patients with unilateral persistent knee arthritis on pain, function, range of motion, and inflammation parameters. Methods N=104 JIA patients diagnosed according to the ILAR criteria with persistent unilateral knee arthritis. They were assigned randomly into two groups; group I received nerve block, group II received intra-articular triamcinolone. Visual analogue scale, SOLAR scoring system, and Lysholm scores were assessed at 0, 2, and 12 weeks intervals. Tenderness and swelling were evaluated by a semi-quantitative score at the same intervals. Results VAS, tenderness, swelling, and SLOAR scores were significantly decreased after 2 weeks of interventions in both groups, but this reduction was greater in GNB group regarding VAS and tenderness, while was greater in steroid group regarding SOLAR and swelling. At 12 weeks, all these outcome measures revealed better values in GNB group in comparison to steroid group, but this was significant only for VAS. Moreover, Lysholm score was significantly increased in both groups at 2 and 12 weeks intervals with higher values in steroid group versus GNB group at 2 weeks. Conclusion Nerve block was able to control pain, improve function and inflammation outcome measures of the knee joint in JIA patients. Although steroid achieved better results after 2 weeks, GNB achieved a better long-term improvement after 12 weeks. Figure 1. References [1]AM Elsaman, A Maaty, and A Hamed, ‘Genicular Nerve Block in Rheumatoid Arthritis: A Randomized Clinical Trial’, Clinical Rheumatology, 40 (2021), 4501-09. Disclosure of Interests None declared
POS1128 SERUM MARKERS OF GUT PERMEABILITY AND ENDOTOXEMIA IN PATIENTS WITH METABOLIC SYNDROME-ASSOCIATED KNEE OSTEOARTHRITIS: AN EXPLORATORY STUDY
Authors: I. Shirinsky, N. Kalinovskaya, V. Shirinsky
Journal: Annals of the Rheumatic Diseases (2022)

Background Metabolic syndrome (MetS)-related osteoarthritis (OA) has been proposed as a distinct phenotype of OA (1). One of the many putative pathways linking MetS with OA is increased gut permeability resulting in endotoxemia, systemic inflammation, and cartilage damage. There is a lack of studies evaluating markers of gut permeability and endotoxemia in patients with MetS-associated OA. Objectives In this exploratory study we aimed to: a. compare serum markers of gut permeability and endotoxemia in patients with knee OA and concomitant MetS vs patients with knee OA b. evaluate possible associations between the studied biomarkers, knee pain, function and body mass index (BMI) in patients with MetS plus OA. Methods In this cross-sectional study, we evaluated consecutive patients diagnosed with knee OA according to ACR criteria and willing to participate in the study. MetS was defined in accordance with NCEP ATP III criteria. Knee pain and function were assessed using the WOMAC scale. Serum concentrations of gut permeability marker zonulin, lipopolysaccharide (LPS), and soluble LPS receptor (sCD14) were measured using commercial ELISA kits. Results Forty patients (19 with OA plus MetS, 21 with OA), all women, mean age 65.5 years, were included in the study. The participants in the compared groups were of similar age. Patients with MetS had significantly higher BMI, increased knee pain, impaired knee function, and elevated serum C-reactive protein levels. Serum LPS, sCD14, and zonulin concentrations were significantly higher (1.5 fold, 2 fold, and 3.5 fold, respectively) in patients with OA+MetS. In the latter group, serum zonulin, sCD14, and LPS concentrations were moderately positively correlated with BMI. There were no correlations between the studied serum biomarkers and WOMAC knee pain, only zonulin was moderately positively associated with WOMAC knee function (Figure 1) Figure 1. Spearman correlation between serum gut permeability markers, BMI, knee pain and function. * - p&lt;0.95, ** - p&lt;0.01 Conclusion These findings suggest that while associated with MetS, increased gut permeability may not play a significant role in OA clinical manifestations. References [1]Courties A, Sellam J, Berenbaum F. Metabolic syndrome-associated osteoarthritis. Curr Opin Rheumatol. 2017 Mar;29(2):214-222. Acknowledgements I have no acknowledgments to declare. Disclosure of Interests None declared
AB1006 IMPACT OF OSTEOARTHRITIS ON THE QUALITY OF LIFE IN PATIENTS WITH KNEE PAIN
Authors: A. Chaidou, K. Veliou, M. Gianniki, M. Migkos, F. Priftis, D. Giotis, N. Tsifetaki
Journal: Annals of the Rheumatic Diseases (2022)

Background Knee osteoarthritis is a common disease which mainly concerns aged population and impairs the quality of life in all aspects. Apart from causing pain or other related biomechanical comorbidities, osteoarthritis might affect phychological and social aspects of life. Objectives The purpose of the study was to investigate the impact of knee osteoarthritis on the quality of life and whether certain factors are related to this impact. Methods In a cross-sectional study, performed in our Hospital from January 2016 to December 2016, 150 patients (127 females and 23 males) with a mean age of 61.8 ± 8.07 years were examined. The sample included outpatients of the Rheumatology Department diagnosed with osteoarthritis and patients displaying knee pain. Individuals who had undergone previous knee surgery, and those with other osteometabolic, rheumatic diseases or chronic degenerative disorders that could interfere with the quality of life, were excluded from the study. All participants, who gave their informed consent, answered the identification questionnaire and were interviewed with the Western Ontario and McMaster Universities Arthritis Index (WOMAC), The World Health Organization Quality of life (WHO QoL) questionnaire, the IPQ and the PHQ-9. All instruments used, were standardized in the Greek context. Results The effect of certain variables including patient associated characteristics, demographics, medical history, drug intake and symptomatology related to osteoarthritis, were evaluated with each of the WHO QoL measurements, the IPQ total score and the WOMAC scale. The regression analysis results demonstrated common significant correlations regarding the presence of injuries, the depression, the increased body mass index (BMI) and occasional crepitus. However, no significant difference was observed between patients with osteoarthritis and patients without osteoarthritis, concerning any of the examined parameters. Conclusion It was demonstrated that quality of life indices were related to agents that are not exclusively met in patients with osteoarthritis which implies that patients` quality of life does not depend on the specific diagnosis but on patient`s psychological aspect (depression), presence of pain (injury) and overall health status (BMI). References [1]Kiadaliri AA, Lamm CJ, de Verdier MG, Engström G, Turkiewicz A, Lohmander LS, Englund M. Association of knee pain and different definitions of knee osteoarthritis with health-related quality of life: a population based cohort study in southern Sweden. Health Qual Life Outcomes. 2016;14(1):121. [2]Neogi T, Nevitt MC, Yang M, Curtis JR, Torner J, Felson DT. Consistency of knee pain: correlates and association with function. Osteoarthritis Cartilage. 2010;18(10):1250–5. Disclosure of Interests None declared
AB0859 Assessment of self-esteem and reintegration to normal living in Spondyloarthritis patients
Authors: T. Mehmli, A. Ben Tekaya, O. Saidane, R. Leila, S. Bouden, R. Tekaya, I. Mahmoud, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2022)

Background Spondyloarthritis is a chronic inflammatory disease involving sacroiliac joints and spine. It mainly affects young patients typically of working age. Pain, reduced spinal mobility and deformities may lead to psychological distress. Objectives The aim of our study was to assess self-esteem and social reintegration in spondyloarthritis patients in comparaison with healthy controls. Methods Fifty patients diagnosed with spondyloarthritis and 50 healthy controls aged less than 50 years old, were included in our study. Clinical, biological and radiological data related to disease were recorded. All subjects completed Reintegration to Normal Living Index (RNLI) and Rosenberg self-esteem scale (SES) questionnaires. Results Our study population included 39 men (78%) and 11 women (22%) with a mean age of 36.8 years [17-50]. Mean disease duration was 11.3 ± 8.2. Mean disease activity scores BASDAI, ASDAS-CRP and ASDAS-ESR were respectively 4.45 ± 1.84, 3.03± 1.06 and 2.74 ± 1. For inflammatory markers, mean CRP and ESR levels were respectively 29.3 ± 41.8 mg/l and 46.5 ± 35.3. Mean BASFI and BASRI scores were respectively 5.21 ± 2.24 and 5.5 ± 2.38. Forty eight pour cent of patients had an extra-articular feature and 47% had coxitis. Regarding treatment, 47% were on TNF inhibitors. Mean SES was 30.6 [25-36]. Fifty six per cent of patients had a low self-esteem (SES&lt;31) and 12% had high self-esteem (SES&gt;34). Self-esteem was within the normal ranges (SES between 31 and 34) in 32% of patients. Mean reintegration to normal life (RNL) adjusted score was 72.8 ± 9.3. Significant association was found between RNL adjusted score and BASDAI (p=0.02, r=0.126) and BASFI (p=0.034, r=0.235). There was no significant association between RNL adjusted score and disease duration (p=0.747), CRP (p=0.213), ESR (p=0.818), ASDAS-ESR (0.747) and ASDAS-CRP (p=0.330) and BASRI scores (p=0.413). No association was found between SES score and disease duration (p=0.447), activity scores BASDAI (p=0.178), ASDAS-ESR (p=0.929) and ASDAS-CRP (p=0.940), ESR (p=0.417) and CRP levels (p=0.828), as well as BASFI (p=0.295) and BASRI (p=0.470). In comparaison with healthy controls, adjusted RNL score was significantly lower in patients with spondyloarthritis (72.8 versus 77.65; p=0,017). In contrast, no significant difference was found between the two groups when comparing SES score (31.4 in spondyloarthritis patients versus 30.6 in healthy controls, p=0.283). Conclusion In our study, spondyloarthritis patients had lower RNL score in comparaison with healthy subjects. Reintegration to normal living was associated with disease activity and functional impairment. In contrast, self-esteem was similar between the two groups. Disclosure of Interests None declared
AB0472 DEFINING AN ACCEPTABLE STATE OF QUALITY OF LIFE IN PRIMARY SJÖGREN’S SYNDROME
Authors: A. Lackner, A. Sanz, S. Zenz, J. Hermann, J. Thiel, M. Stradner
Journal: Annals of the Rheumatic Diseases (2022)

Background The PSS-QoL (the Primary Sjögren’s Syndrome Quality of Life Questionnaire) is a disease-specific health-related quality of life (HRQL) questionnaire in primary Sjögren Syndrome (PSS). The psychometric testing showed a valid and reliable assessment, which allows a comprehensive evaluation of the patients’ perspective and the extent of the disease in PSS. Objectives To define the threshold of an acceptable QoL state (AQLS) and the minimal detectable change (MDC) of the PSS-QoL. Methods Data of patients from the PSS registry of the Medical University of Graz fulfilling the 2016 ACR/EULAR classification criteria for PSS were analysed. Patients completed the PSS-Qol and ESSPRI (EULAR Sjögren’s syndrome patient-reported index), disease activity was assessed by the ESSDAI (EULAR Sjögren’s syndrome disease activity index) and an evaluator’s global assessment (EGA, scale from 0 to 10). Receiver operating characteristic curve analyses were used to estimate the AQLS based on patients’ assessment on the extent of HRQL. We selected the optimal cut-off of PSS-QoL by the maximal Youden index. At the follow – up visits after 12 months, patients assessed, whether their HRQL had changed. An anchoring method based on this evaluation was used to estimate the MDC of PSS-QoL. Furthermore, clinical data were compared in AQLS and non-AQLS groups. Results Data from 152 PSS patients were analysed which of 91.4% (n=139) were female. The mean age was 59.65±12.3 years (± standard deviation) and the mean disease duration was 5.6±5.3 years. The AQLS estimate was defined as PSS-QoL≤29.5. 40.1% (n=61) were categorized to be in AQLS. Although AQLS patients were significantly younger (56.9±13.1years vs 61.5±11.4 years, p&lt;0.01) they had a longer disease duration (6.9±5.8 years vs. 4.7±4.7 years, p&lt;0.05) compared to non-AQLS patients. AQLS patients had a lower EGA (2 [0-5] vs 3 [0-7], p&lt;0.01 (median [range]), higher IgG (15.7[7.7-33.8, range] vs 13.1 [6.5-38.1], p&lt;0.05) and higher rheumatoid-factor IgA (84 [0-500] vs 20 [0-500], p&lt;0.01). AQLS patients showed significantly lower burden of sicca (measured by ESSPRI and sicca VAS scores). The MDC for PSS-QoL was defined as 12.2 points. After one year, patients’ HRQL did not change in 83.3% and got worse 7.1%. Conclusion This study determined the AQLS and the minimal detectable change for HRQL. These results will help evaluating the HRQL of patients in clinical practice, as well as possible assistance designing future clinical trials. Patients in AQLS show lower dryness scores but higher immunological activity compared to non-AQLS patients. Longitudinal studies are needed to determine factors affecting patients’ HRQL in PSS. Disclosure of Interests None declared
POS1266 MULTICENTER RETROSPECTIVE STUDY EVALUATING THE SAFETY OF ANTI-SARS-CoV-2 VACCINE IN A COHORT OF PATIENTS WITH SYSTEMIC VASCULITIS
Authors: E. Simoncelli, S. Colafrancesco, F. R. Spinelli, A. Gattamelata, F. Giardina, S. Truglia, C. Garufi, R. Izzo, L. Cantarini, B. Frediani, E. Conticini, S. Grazzini, R. Priori, F. Conti
Journal: Annals of the Rheumatic Diseases (2022)

Background Vaccinations against SARS-CoV-2 represent a fundamental tool in controlling the pandemic. To date, data on the safety of anti-SARS-CoV-2 vaccines in patients with rare rheumatic diseases, such as systemic vasculitis, are limited. Objectives In this study we aimed at evaluating the safety of anti-SARS-CoV-2 vaccines in a multicentric cohort of patients with systemic vasculitis. Methods Patients with systemic vasculitis from two Rheumatology centres who had received anti-SARS-CoV-2 vaccine were retrospectively examined. The primary outcome was to evaluate, in this multi-centric cohort, the occurence of a disease flare after the administration of the vaccine, defined as development of clinical manifestations related to vasculitis with a concomitant increase in serum inflammatory markers. As a secondary outcome we aimed at evaluating, in a monocentric cohort of patients with vasculitis, the occurrence of adverse events (AEs) following vaccine administration compared to healthy controls (HC). Results We examined 111 patients with systemic vasculitis (n=69 female, n=42 male), with a mean age of 64.3 (± 13) years. Sixty had ANCA-associated vasculitis (AAV), fourty-two had Giant-Cell Arterities (GCA), five had Periarteritis Nodosa, four had Takayasu’s arteritis. One-hundred and five patients received a mRNA vaccine and six a viral vector one. A disease flare occurred in only 2 patients (1.8%) after the first dose of a mRNA vaccine: both had AAV (microscopic poliangioitis) and developed a pulmunary disease flare (respiratory failure requiring hospitalization and treatment with high-dose glucocorticoids). Of note, one of these patients had multiple previous comorbidities, including a severe COPD. Multivaried analysis, adjusted for age and sex, performed in a single monocentric cohort of patients with systemic vasculitis [n=60 (39 AAV, 21 GCA), 37 female, 23 male, mean age 71 (± 12.5) years] demonstrated a statistically significant higher frequency of AEs in vasculitis patients compared to HC (p=0.015) after the first dose of vaccination. No significant differences in the frequency of AEs in vasculitis patients compared to HC after the second dose were detected. All the AEs were mild in both groups (malaise was the most frequently reported); no serious AEs were reported. Conclusion Our data show a very low incidence of disease flares after the administration of anti-SARS-CoV-2 vaccines in patients with systemic vasculitis. Patients with systemic vasculitis seem more prone to develop mild AEs after the first dose of the vaccine. Taken together, this data suggest a good risk profile for anti-SARS-CoV-2 vaccine in patients with systemic vasculitis. Disclosure of Interests None declared
AB1249 IMPACT OF OVERWEIGHT AND OBESITY ON HIP INVOLVEMENT IN JUVENILE IDIOPATHIC ARTHRITIS
Authors: H. Ferjani, M. Yasmine, H. Affes, K. Maatallah, W. Triki, D. Ben Nessib, D. Kaffel, M. Jenzri, W. Hamdi
Journal: Annals of the Rheumatic Diseases (2022)

Background The prevalence of obesity among children is on the rise, becoming a worldwide epidemic. The overweight is also associated with mechanical stress in the weight-bearing joint especially in the hip joint. Previous studies showed that increased Body mass index was a predicting factor of a poor outcomes [1]. Objectives In this regard, we proposed to evaluate the effect of obesity on hip involvement in JIA patients. Methods We conducted a cross-sectional study including children with JIA according to the International League of Associations for Rheumatology (ILAR)). Transcribed data included age, sex and the characteristics of the disease (subtype of JIA, disease duration). Data on hip involvement was also collected. Weight and height of each patient was recorded. The body mass index (BMI) was calculated (Kg/m 2 ). We compared these parameters between two groups: G1: presence of coxitis and G2: absence of coxitis. Results The study included 62 patients with a male perdominance: sex ratio was 2.3. The mean age of onset of the disease was 11.4 years [3-16].The frequency of each JIA subset was at follows: polyarticular with rheumatoid factor (n=2), polyarticular without rheumatoid factor (n=4), systemic (n= 1), enthesitis-related arthritis (n=44), oligoarthritis (n=8), psoriatic arthritis (n=3). Hip involvement was reported in 71 % of cases and was bilateral in 81% of patients. The mean weight (Kg) and height (meter) was similar between the two groups (57.4 in G1 vs 53.6 in G2, p=0.486) and (1.61 in G1 vs 1.58 in G2, p=0.483) respectively. The prevalence of overweight patients was higher in G1 than G2 without reaching a statistically significant correlation (23% vs 12.5%, p=0.518). Similarly, there was no statistically significant correlation between the body mass index (Kg/m 2 ) and coxitis (22.2 vs 21, p=0.45). Moreover, a higher BMI was not associated with a limited range of motion as well as hip replacement (p=0.7, p=0.1 respectively). Conclusion Our study showed that BMI did not impact hip involvement in juvenile idiopathic arthritis patients. As obesity confers an additional health risk, addressing this co-morbidity should be a health priority in these patients. References [1]Makay B, Gücenmez ÖA, Ünsal E. Inactive Disease in Enthesitis-related Arthritis: Association of Increased Body Mass Index. J Rheumatol. 2016;43(5):937-43. Disclosure of Interests None declared
AB1014 FRACTURES REDUCTION WITH OSTEOPOROTIC TREATMENTS IN PATIENTS OVER 75-YEAR-OLD: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: M. Guillaumin, B. Poirson, A. Gerazime, M. Puyraveau, T. Tannou, F. Mauny, E. Toussirot
Journal: Annals of the Rheumatic Diseases (2022)

Background Osteoporosis consists in the reduction of bone mineral density and increased fracture risk. Age is a risk factor for osteoporosis. Although many treatments are available in osteoporosis, there is limited data regarding their efficacity in older people. Objectives We aimed to evaluate the efficacy of osteoporosis treatments in patients over 75 years old. Methods we reviewed all published studies in MEDLINE, COCHRANE and EMBASE including patients over 75-year-old treated by osteoporosis drugs and focused on vertebral fractures or hip fractures. Results we identified 4393 records for review. 4216 were excluded after title/abstract review. After full text review, 19 records were included in systematic review. Most of the studies showed a reduction of vertebral fracture with osteoporosis treatments but non-significant results were observed for hip fractures. Meta-analysis of 10 studies showed that osteoporosis treatments significantly reduced the occurrence of vertebral fractures at one (OR=3.67; 95%CI=2.50-5.38) and three years (OR=2.19; 95%CI= 1.44-3.34) as well as those of hip fractures at one (OR=2.14; 95%CI=1.09-4.22) and three years (OR=1.31, 95%IC=1.12-1.53). Conclusion osteoporotic treatments showed to be effective in the reduction of vertebral and hip fractures in older people. However, majority of data derived from post hoc and pre-planned analyses or observational studies. Disclosure of Interests None declared
AB0271 ALEXITHYMIA IN A PATIENT WITH RHEUMATOID ARTHRITIS: CONNECTION WITH DISEASES AND FUNCTIONAL ABILITY.
Authors: Y. Shalkovskyi, M. Stanislavchuk
Journal: Annals of the Rheumatic Diseases (2022)

Background Rheumatoid arthritis (RA) is the chronic, destructive, immune-mediated inflammatory disease that has a progressive course and causes the early disability of approximately 50% over the next five years. Acute pain syndrome in RA often leads to a violation of the psycho-emotional sphere with manifestations in the form of depression, anxiety and alexithymia. 1 Alexithymia is defined as a personal emotional disorder characterized by difficulty in identifying and describing subjective feelings and related to cognitive impairment. There is insufficient data regarding the prevalence of alexithymia in patients with RA. Objectives To investigate the prevalence of alexithymia and the relationship with disease activity and functional ability in patients with RA. Methods RA patients diagnosed according to the ACR/EULAR 2010 classification criteria. The presence of alexithymia was determined by the «Toronto Alexithymia Scale» questionnaire (TAS-20). RA activity was assessed by the Disease Activity Score (DAS28-ESR), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI). Functional ability - by the Health Assessment Questionnaire (HAQ). In the study were included 98 patients with RA (83.7% of women). The mean age was (M±SD) 49.5 ± 11.7 years, the duration of the disease ranged from 1 to 21 years, and averaged 7.8 ± 4.9 years. Statistical analysis was performed by IBM Statistics SPSS 20. Results Among 98 examined, alexithymia (≥ 61) was detected in 24 persons (24.5%), including 23 women, mean age (M ± SD) 54 ± 7.16 years with disease duration 9.96 ± 5.23 years. The activity of RA in persons with alexithymia was: DAS-28 (6.4 ± 0.71); SDAI (41.15 ± 8.64); CDAI (39.46 ± 9.03) and ESR (27.6 ± 15.1), which was significantly higher than in patients without alexithymia: DAS-28 (5.52 ± 1.05); SDAI (32.72 ± 11.28); CDAI (31.98 ± 11.07) and ESR (22.7 ± 15.27). Functional disability in individuals with RA and alexithymia according to HAQ was (1.7 ± 0.59) in contrast to the group of patients with RA without alexithymia - (1.04 ± 0.62). The value of TAS-20 had a direct correlation with the activity by DAS-28 (0,379; p &lt; 0,01), SDAI (0,39; p &lt; 0,01) and CDAI (0,359; p &lt; 0,01)), radiological stage (0.260; p &lt; 0.01) and HAQ (0.393; p &lt; 0.01). Conclusion Alexithymia is quite common comorbid condition in patients with RA associated with disease activity and functional disability. Further studies are needed to assess the clinical significance of alexithymia in this category of patients. References [1]Larice, S., Ghiggia, A., Di Tella, M., Romeo, A., Gasparetto, E., Fusaro, E., Castelli, L., &amp; Tesio, V. (2020). Pain appraisal and quality of life in 108 outpatients with rheumatoid arthritis. Scandinavian journal of psychology , 61 (2), 271–280. https://doi.org/10.1111/sjop.12592 Disclosure of Interests None declared